Document is current
Any future updates will be listed below
-
Authors
Tsai, Jonathan M.
Nowak, Radosław P. https://orcid.org/0000-0002-0605-0071
Ebert, Benjamin L. https://orcid.org/0000-0003-0197-5451
Fischer, Eric S. https://orcid.org/0000-0001-7337-6306
- License Information
-
More Information
Article History
Accepted: 21 March 2024
First Online: 29 April 2024
Competing interests
: E.S.F. is a founder, member of the scientific advisory board and equity holder of Civetta Therapeutics, Proximity Therapeutics and Neomorph, Inc. (also board of directors). He is an equity holder and scientific advisory board member for Avilar Therapeutics and Photys Therapeutics, an equity holder in Lighthorse Therapeutics and a consultant to Novartis, Sanofi, EcoR1 Capital, Ajax, Odyssey and Deerfield. The Fischer lab receives or has received research funding from Deerfield, Novartis, Ajax, Bayer, Interline and Astellas. B.L.E. has received research funding from Celgene, Deerfield, Novartis and Calico and consulting fees from GRAIL. He is a member of the scientific advisory board and shareholder for Neomorph Inc., TenSixteen Bio, Skyhawk Therapeutics and Exo Therapeutics. R.P.N. and J.M.T. declare no competing interests.
